Product Highlight - Fluticasone furoate, umeclidinium Br, vilanterol trifenatate (Trelegy Ellipta)

Striving for a life uninterrupted, ONE day, ONE dose at a time.

• Fluticasone furoate/Umeclidinium/Vilanterol (TRELEGY Ellipta) is number one for single-inhaler Triple Therapy prescriptions worldwide and has provided benefits for over millions of patients.¹

• The only single inhaler triple therapy with direct head-to-head evidence of superior component molecules within LAMA, LAMA/LABA, and ICS/LABA classes.^2-5

• The world’s only once daily single inhaler triple therapy licensed for COPD.⁶

• Join fellow respiratory physicians worldwide and prescribe now for your symptomatic COPD patients at risk of exacerbation.

References:
1. IQVIA market sales data. 2022. Reference on file.
2. Feldman G et al. Int J Chron Obstruct Pulmon Dis 2016; 11:719-730.
3. Daley-Yates PT et al. Br J Clin Pharmacol 2020. doi: 10.1111/bcp.14406.
4. Maltais F et al. Adv Ther 2019; 36:2434-2449
5. Feldman GJ et al. Adv Ther 2017; 34:2518-2533.
6. Trelegy Prescribing Information version number: GDS06/IPI06. 1 Revision date: 08 June 2021.